Kyverna Therapeutics (KYTX)

• Market cap: $301M
• 1 day: 3.26%
• 5 days: -11.55%
• 1 month: 16.17%
• 3 months: 95.24%
• 6 months: 201.73%
• Year to date: 77.81%
• 1 year: 45.82%
• 5 years: -76.77%
• 10 years: -76.77%
• Sector: Healthcare
• Industry: Biotechnology

About: Kyverna Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on developing cell therapies for patients suffering from autoimmune diseases. Its product, KYV-101, is an autologous CD19 CAR T-cell product candidate made from an underlying chimeric antigen receptor, or CAR. It is also developing KYV-201, an allogeneic therapy containing the same CAR as KYV-101, to develop it in multiple autoimmune diseases.

Employees: 129